Skip to main content

Table 1 Summary of the results of combined models for pre- and post- highly active antiretroviral therapy (HAART) CD4 cell count data, after square root transformation, for patients from the UK Register of HIV Seroconverters dataset

From: Combined models for pre- and post-treatment longitudinal biomarker data: an application to CD4 counts in HIV-patients

 

M o d e l 1

M o d e l 2

M o d e l 3

M o d e l 4

M o d e l 5

M o d e l 6

β 0

22.44 (22.13 to 22.74)

22.45 (22.16 to 22.74)

22.44 (22.15 to 22.73)

22.26 (21.96 to 22.56)

22.26 (21.96 to 22.56)

22.23 (21.94 to 22.53)

β 1

−1.36 (−1.52 to −1.2)

−1.39 (−1.55 to −1.23)

−1.39 (−1.55 to −1.23)

−1.3 (−1.46 to −1.14)

−1.32 (−1.47 to −1.16)

−1.36 (−1.5 to −1.21)

U 00

12.37 (10.64 to 14.37)

13.39 (11.77 to 15.23)

13.42 (11.79 to 15.28)

14.43 (12.68 to 16.43)

14.53 (12.77 to 16.54)

12.92 (11.29 to 14.8)

ρ

−0.65 (−0.79 to −0.44)

−0.86 (−0.99 to 0.18)

−0.84 (−0.98 to −0.1)

−0.95 (−1 to 1)

−0.92 (−1 to 0.91)

−0.63 (−0.76 to −0.44)

U 11

0.55 (0.33 to 0.93)

0.25 (0.08 to 0.75)

0.28 (0.1 to 0.75)

0.2 (0.05 to 0.74)

0.21 (0.06 to 0.74)

0.49 (0.31 to 0.77)

κ pre

9.68 (8.77 to 10.68)

5.91 (5.23 to 6.67)

5.9 (5.22 to 6.68)

5.99 (5.29 to 6.8)

5.92 (5.21 to 6.72)

5.37 (4.37 to 6.6)

H pre

0.11 (0.09 to 0.14)

0.3 (0.25 to 0.37)

0.3 (0.24 to 0.36)

0.31 (0.25 to 0.37)

0.31 (0.25 to 0.38)

0.16 (0.13 to 0.19)

σ

1.25 (1.09 to 1.42)

1.95 (1.89 to 2.01)

1.94 (1.87 to 2)

1.92 (1.85 to 1.99)

1.92 (1.86 to 1.99)

1.32 (1.19 to 1.46)

ϕ1 model:

 

long-term

Constant for all patients

Linear for all patients

NCS for all patients

Linear for all patients

Linear for early treatment

Linear for all patients

maximum

   

stratified by ART t

groups or NCS for late

stratified by ART t

     

treatment group

 

At11

7.04 (4.75 to 9.33)

7.06 (4.77 to 9.35)

8.44 (6.05 to 10.83)

At12

0.9 (0.79 to 1.01)

0.9 (0.79 to 1)

0.84 (0.72 to 0.95)

At21

10.73 (7.93 to 13.53)

10.68 (7.85 to 13.51)

12.32 (9.28 to 15.35)

At22

0.67 (0.54 to 0.81)

0.67 (0.53 to 0.81)

0.64 (0.47 to 0.8)

A 1

25.93 (25.49 to 26.36)

11.42 (9.74 to 13.09)

5.1 (0.3 to 9.9)

14.58 (12.3 to 16.86)

3.76 (−1.99 to 9.51)

14.35 (12.32 to 16.38)

A 2

0.69 (0.62 to 0.77)

1.14 (0.84 to 1.44)

0.55 (0.44 to 0.66)

1.23 (0.86 to 1.6)

0.57 (0.46 to 0.67)

A 3

-0.43 (−0.64 to −0.22)

−0.32 (−0.63 to −0.01)

A 4

0.82 (0.43 to 1.2)

0.52 (−0.07 to 1.11)

ϕ2 model:

 

recovery

Constant for all patients

Linear for all patients

NCS for all patients

Linear for all patients

Linear for early treatment

Linear for all patients

speed

   

stratified by ART t

groups or NCS for late

stratified by ART t

     

treatment group

 

Bt11

2.66 (0.52 to 4.79)

2.8 (0.76 to 4.84)

5.68 (2.94 to 8.43)

Bt12

0.02 (−0.08 to 0.11)

0.01 (−0.08 to 0.1)

−0.14 (−0.29 to −1.98e-03)

Bt21

−0.99 (−3 to 1.02)

−0.92 (−2.97 to 1.13)

0.23 (−1.39 to 1.86)

Bt22

0.15 (0.05 to 0.26)

0.15 (0.04 to 0.26)

0.01 (−0.1 to 0.12)

B 1

-0.16 (−0.3 to −0.02)

−3.34 (−4.19 to −2.48)

1.82 (−0.23 to 3.87)

−3.64 (−4.7 to −2.59)

2.42 (0.26 to 4.58)

−2.25 (−3.3 to −1.21)

B 2

0.24 (0.2 to 0.28)

−0.11 (−0.24 to 0.02)

0.23 (0.17 to 0.29)

−0.15 (−0.29 to −0.02)

0.13 (0.07 to 0.19)

B 3

0.28 (0.19 to 0.38)

0.19 (0.04 to 0.33)

B 4

−0.52 (−0.71 to −0.33)

−0.28 (−0.58 to 0.02)

P

11.09 (8.76 to 14.03)

2.97 (2.09 to 4.23)

3.05 (2.13 to 4.38)

3.07 (2.19 to 4.31)

3.31 (2.39 to 4.59)

2.72 (1.71 to 4.31)

κ post

7.59 (6.79 to 8.49)

3.09 (2.46 to 3.89)

3.17 (2.53 to 3.98)

3.36 (2.7 to 4.18)

3.3 (2.66 to 4.11)

4.33 (3.5 to 5.36)

H post

0.08 (0.07 to 0.1)

0.42 (0.32 to 0.52)

0.4 (0.3 to 0.5)

0.38 (0.29 to 0.48)

0.39 (0.3 to 0.5)

0.13 (0.11 to 0.16)

Differences in variability

 

between patients

No

No

No

No

No

Yes

d f pre

3.84 (3.06 to 4.82)

d f post

4.28 (3.4 to 5.38)

ρ Moran

0.37 (0.19 to 0.52)

n pars

13

15

19

23

27

26

−31954.8

−31724.6

−31708.9

−31664.5

−31656.5

−31299.7a

BIC

64032.85

63591.41

63597.94

63547.06

63568.98

62845.9 a

  1. Parameter estimates are given with 95% confidence intervals in parentheses. aNot comparable to other values in Table, as calculated using Laplace approximation. ART t , time from seroconversion to treatment initiation; BIC, Bayesian information criterion; , log-likelihood; NCS, natural cubic spline; n pars , number of parameters estimated in model The interpretation of each model parameter is listed in Table 2